Table 1.
Use of Stop Smoking Medications 2006, 2007, and 2008.
| 2006 | 2007 | 2008 | ||||
|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |
| United States | 1,025 | 1,021 | 658 | |||
| Any SSM | 24.4 | 33.0 | 48.8 1 | |||
| NRT | 19.5 | 16.5 | 22.2 | |||
| Bupropion | 4.8 | 3.4 | 4.3 | |||
| Varenicline | 0.4 | 13.7 | 21.7 1 | |||
| United Kingdom | 903 | 843 | 704 | |||
| Any SSM | 31.9 | 36.3 | 36.6 1 | |||
| NRT | 29.8 | 32.7 | 29.1 | |||
| Bupropion | 1.9 | 1.1 | 2.0 | |||
| Varenicline | 0.0 | 2.0 | 4.41 | |||
| Canada | 975 | 927 | 676 | |||
| Any SSM | 31.1 | 32.3 | 45.7 1 | |||
| NRT | 26.8 | 24.1 | 24.6 | |||
| Bupropion | 4.8 | 5.5 | 5.5 | |||
| Varenicline | 0.0 | 2.3 | 14.8 1 | |||
| Australia | 1,119 | 999 | 697 | |||
| Any SSM | 31.5 | 35.3 | 45.6 1 | |||
| NRT | 26.0 | 29.8 | 24.5 | |||
| Bupropion | 5.2 | 5.1 | 5.6 | |||
| Varenicline | 0.0 | 0.12 | 14.5 1 | |||
1
indicates statistically significant chi-square for trend at the p < 0.001 level
2
Of 141 respondents interviewed after on market date, 1 participant (0.7%) reported using varenicline